Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

AstraZeneca PLC ADR (AZN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow AstraZeneca ADR's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
66.07 -0.95    -1.42%
30/06 - Closed. Currency in USD ( Disclaimer )
Pre Market
64.95
-1.12
-1.70%
11:31:34 - Real-time Data
  • Volume: 4,700,031
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 65.19 - 66.42
Type:  Equity
Market:  United States
ISIN:  US0463531089 
CUSIP:  046353108
AstraZeneca ADR 66.07 -0.95 -1.42%
  • General    
  • Chart    
  • News & Analysis    
  • Financials    
  • Technical    
  • Forum    
  • InvestingPro

For the three months ended 31 March 2022, AstraZeneca plc (ADR) revenues increased 56% to $11.39B. Net income decreased 75% to $386M. Revenues reflect Farxiga segment increase of 60% to $1B, Calquenc segment increase of 98% to $414M, United States segment increase of 79% to $4.13B, Established ROW segment increase from $96M to $1.61B. Net income was offset by acquisition-related costs and credits increase from $0K to $1.18B (expense).

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

AZN Income Statement

Gross margin TTM 72.61%
Operating margin TTM 0.09%
Net Profit margin TTM -2.55%
Return on Investment TTM -1.75%
 Total Revenue  Net Income
Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Total Revenue 11390 12011 9866 8220
Gross Profit 9111 8942 6042 6027
Operating Income 878 -292 -1674 1127
Net Income 386 -347 -1652 550

AZN Balance Sheet

Quick Ratio MRQ 0.66
Current Ratio MRQ 1
LT Debt to Equity MRQ 79.27%
Total Debt to Equity MRQ 85.58%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Total Assets 100273 105363 107221 73641
Total Liabilities 63933 66095 67477 57965
Total Equity 36340 39268 39744 15676

AZN Cash Flow Statement

Cash Flow/Share TTM 2.02
Revenue/Share TTM 14
Operating Cash Flow  14.21%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Period Length: 3 Months 12 Months 9 Months 6 Months
Cash From Operating Activities 3232 5963 4545 2826
Cash From Investing Activities -168 -11058 -10145 319
Cash From Financing Activities -3740 3649 4700 4558
Net Change in Cash -685 -1508 -973 7651
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AZN Comments

Write your thoughts about AstraZeneca PLC ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai May 09, 2021 11:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thanks you AstraZ. Bullish. management services.
Woon soo Lee
Woon soo Lee May 01, 2021 18:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
54 to 64 bullish sentiments again volatility trading
Poh Meng Kong
Poh Meng Kong Feb 25, 2021 22:08
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$68 in 1 month
Nelson T Machin
Nelson T Machin Feb 01, 2021 15:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Do you this will grow as EU has approved their Covid vaccine?
Frans Caruana
Frans Caruana Jan 25, 2021 20:45
Saved. See Saved Items.
This comment has already been saved in your Saved Items
will reach 100 in 6 months time
Arek Rusak
Arek Rusak Dec 24, 2020 13:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think the vaccine is nothing next to the antibody coctail, known as AZD7442 that Astra is working on at the momenthttps://www.reuters.com/article/health-coronavirus-astrazeneca-antibody-idUSKBN28100E
bojidar zarev
bojidar zarev Dec 14, 2020 18:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good buy in the long term.
Andre Low
Andre Low Dec 12, 2020 13:18
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.wsj.com/articles/astrazeneca-agrees-to-buy-alexion-for-39-billion-11607778687?redirect=amp#click=https://t.co/EeYlRyEn3g
Nabeel Qabane
Nabeel Qabane Nov 30, 2020 10:27
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I expect it to reach $ 100 next month
Sandeep Agarwal
Sandeep Agarwal Oct 12, 2020 17:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
for super rich returns
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email